Envestnet Asset Management Inc. Raises Holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Envestnet Asset Management Inc. boosted its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 15.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 618,691 shares of the medical equipment provider's stock after buying an additional 83,341 shares during the period. Envestnet Asset Management Inc. owned 0.14% of Smith & Nephew SNATS worth $17,552,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Hexagon Capital Partners LLC increased its holdings in shares of Smith & Nephew SNATS by 63.3% in the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 406 shares during the last quarter. National Bank of Canada FI lifted its position in Smith & Nephew SNATS by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after acquiring an additional 446 shares during the period. Bessemer Group Inc. lifted its position in Smith & Nephew SNATS by 3,471.4% during the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 1,701 shares during the period. Hara Capital LLC lifted its position in Smith & Nephew SNATS by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after acquiring an additional 1,957 shares during the period. Finally, Opal Wealth Advisors LLC acquired a new stake in Smith & Nephew SNATS during the 1st quarter worth approximately $73,000. Institutional investors and hedge funds own 25.64% of the company's stock.

Wall Street Analysts Forecast Growth

SNN has been the subject of several recent analyst reports. Canaccord Genuity Group raised their price target on Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a report on Thursday, May 1st. Hsbc Global Res cut Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, HSBC cut Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Six equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $28.00.

Smith & Nephew SNATS Trading Up 1.1%

Shares of NYSE SNN opened at $29.90 on Friday. The stock's 50 day moving average price is $29.44 and its two-hundred day moving average price is $27.60. Smith & Nephew SNATS, Inc. has a 52-week low of $23.69 and a 52-week high of $31.72. The stock has a market capitalization of $13.09 billion, a P/E ratio of 13.84, a PEG ratio of 0.90 and a beta of 0.69. The company has a quick ratio of 1.33, a current ratio of 2.89 and a debt-to-equity ratio of 0.62.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.